Enanta Pharmaceuticals | Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.81B 13.45B 2025-12
Amgen USD 5.9B 773M 2025-12
Anika Therapeutics USD 146.8M 867K 2025-09
Arrowhead Research USD 223.22M 10.86M 2025-12
AstraZeneca USD 16.69B 5.74B 2025-09
BioCryst Pharmaceuticals USD -387.89M 33.7M 2025-09
Biogen USD 1.88B 81.4M 2025-09
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Enanta Pharmaceuticals USD 79.28M 14.26M 2025-06
Gilead Sciences USD 4.26B 95M 2025-09
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Halozyme Therapeutics USD 136.34M 13.06M 2025-09
Heron Therapeutics USD 38.47M 4M 2024-09
Immunic USD 25.73M 2.91M 2024-09
Incyte USD 1.12B 3.53B 2025-12
Insmed USD 403.69M 42.4M 2025-09
Ionis Pharmaceuticals USD 316.9M 4.69M 2025-09
J&J USD 18.97B 2.38B 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
Merck USD 10.16B 558M 2025-12
Neurocrine Biosciences USD 555.6M 13.7M 2025-09
Novartis USD 9.86B 115M 2025-09
Novavax USD 218.53M 34.86M 2024-09
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 207.52M 6.21M 2025-09
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 462.23M 33.28M 2025-09
Vertex Pharmaceuticals USD 1.84B 27.1M 2025-09


Enanta Pharmaceuticals Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.